Table 4 Selected SBRT series in patients with primary and secondary liver tumors
Author, Year Study-Type | n (patients) n (lesions) | n (primary LT) n (metastases) | GTV volume (median/range)a | 1 yr-LC (%) (HCC/MD) | 1 yr-OS (%) (HCC/MD) | Toxicity Gr3+ (%) |
|---|---|---|---|---|---|---|
Mendez-Romero et al. 2006 Phase I/II | 25 45 | HCC: 11 MD: 34 | 3.5 (0.5–7.2) | 94 (75/100) | 82 (75/85) | 12.5 |
Goodman et al. 2010 Phase I | 26 40 | HCC/CCC: 7 MD: 19 | 32.6 (0.8–146.6) | 77 | 62 | 0 |
Own data | 55 70 | HCC: 27 MD: 28 | 6.6 (0.2–204) | 91 (92/89) | 76 (68/84) | 5b |
Bujold et al. 2013 Phase I/II | 102 | HCC only | 7.2 (1.4–23.1) | 87 | 55 | 30 |
Lasley et al. 2015 Phase I/II | 59 59 | HCC only | 33.6 (2.2–107.3) | 91 (Child A) 82 (Child B) | 94 (Child A) 57 (Child B) | 11 (Child A) 38 (Child B) |
Own data | 27 36 | HCC only | 7.5 (0.9–204) | 92 | 68 | 11b |
Scorsetti et al. 2015 Phase I/II | 42 52 | MD only | 3.5 (1.1–5.4) | 91 (2 yr) | 65 (2 yr) | 0 |
Andratschke et al. 2015 Retro, pooled | 74 91 | MD only | n.r. | 75 | 77 | 0 |
Own data | 28 34 | MD only | 6.2 (0.2–98.2) | 89 | 84 | 0 |